Structure via PubChem · Public domain (PubChem)
sevelamer
Sign in to saveAlso known as Sévélamer, Sevelamero, Sevelamerum
Sevelamer (rINN) is a phosphate binding medication used to treat hyperphosphatemia in patients with chronic kidney disease. When taken with meals, it binds to dietary phosphate and prevents its absorption. Sevelamer was invented and developed by GelTex Pharmaceuticals. Sevelamer is marketed by Sanofi under the brand names Renagel (sevelamer hydrochloride) and Renvela (sevelamer carbonate).
Chemical data
- Formula
- C6H12ClNO
- Molecular weight
- 149.62 g/mol
- IUPAC name
- 2-(chloromethyl)oxirane;prop-2-en-1-amine
- SMILES
- C=CCN.C1C(O1)CCl
- InChIKey
- ZNSIZMQNQCNRBW-UHFFFAOYSA-N
- Polar surface area
- 38.6 Ų
- H-bond donors
- 1
- H-bond acceptors
- 2
- Formal charge
- 0
via PubChem
Research
1,140 papers- Sevelamer.Nephron. Clinical practice · 2003
- Sevelamer carbonate.The Annals of pharmacotherapy · 2010
- Efficacy and Safety of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in Chinese Dialysis Patients with Hyperphosphataemia: A Randomised, Open-Label, Multicentre, 12-Week Phase III Study.Nephron · 2024
- [Sevelamer:hydrochloride].Clinical calcium · 2005
- Sevelamer versus calcium-based phosphate binders for chronic kidney disease.Medwave · 2017
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 154.09212541399998
- Has use
- medication
Show 7 more facts
- chemical formula
- C₆H₁₂ClNO
- medical condition treated
- hyperphosphatemia
- canonical SMILES
- C=CCN.C1C(O1)CCl
- isomeric SMILES
- [2H]C1(C(O1)([2H])C([2H])([2H])Cl)[2H].C=CCN
- defined daily dose
- 6.4
- NCI Thesaurus ID
- C84172
- Commons category
- Sevelamer
via Wikidata · CC0
~2 min read
Encyclopedic overview
6 sectionsContents
- Chemistry and pharmacology
- Medical uses
- Contraindications
- Adverse effects
- Other effects
- References
Sevelamer (rINN) is a phosphate binding medication used to treat hyperphosphatemia in patients with chronic kidney disease. When taken with meals, it binds to dietary phosphate and prevents its absorption. Sevelamer was invented and developed by GelTex Pharmaceuticals. Sevelamer is marketed by Sanofi under the brand names Renagel (sevelamer hydrochloride) and Renvela (sevelamer carbonate).
==Chemistry and pharmacology== Sevelamer consists of polyallylamine that is crosslinked with epichlorohydrin. The marketed form sevelamer hydrochloride is a partial hydrochloride salt being present as approximately 40% amine hydrochloride and 60% sevelamer base. The amine groups of sevelamer become partially protonated in the intestine and interact with phosphate ions through ionic and hydrogen bonding.
Excerpted from Wikipedia’s “sevelamer” article, available under the CC BY-SA 4.0 licence.